Gastroenterology

Gastroenterology

Volume 89, Issue 5, November 1985, Pages 1005-1013
Gastroenterology

Intensive intravenous treatment of ulcerative colitis

https://doi.org/10.1016/0016-5085(85)90201-XGet rights and content

Abstract

Two hundred four courses of intensive intravenous treatment were given to 158 patients with ulcerative colitis. The remission rates in the severe, moderate, or mild attacks were 55.7%, 86.9%, and 91.8%. Total colitis had a great impact on the results, especially in severe attacks. Of these patients, 52.8% were operated on within 3 wk. The relapse rate was exponential, and during the first year 48.1% of the patients in remission relapsed. The extent of the colitis, severity of the attack, or duration of intensive intravenous treatment had no influence on the time of relapse. Twelve patients with chronic continuous disease were given intensive intravenous treatment. No long-term benefit was seen in patients with total ulcerative colitis, but half of those with less extensive colitis showed a good to excellent response to treatment.

References (33)

  • FC Edwards et al.

    The course and prognosis of ulcerative colitis

    Gut

    (1963)
  • ND Gallagher et al.

    The management of fulminant ulcerative colitis

    Gut

    (1962)
  • JC Goligher et al.

    Surgical treatment of severe attacks of ulcerative colitis with special reference to the advantages of early operation

    Br Med J

    (1970)
  • H Schjønsby et al.

    Intensive treatment in severe acute attacks of ulcerative colitis

    Acta Med Scand

    (1977)
  • A Flatmark et al.

    Early colectomy in severe ulcerative colitis

    Scand J Gastroenterol

    (1975)
  • SC Truelove et al.

    Cortisone in ulcerative colitis. Final report on a therapeutic trial

    Br Med J

    (1955)
  • Cited by (318)

    • Cytapheresis (CAP) with leukocyte removal filter/bead column as one therapeutic option for inflammatory bowel disease

      2017, Transfusion and Apheresis Science
      Citation Excerpt :

      Instead, patients in acute severe exacerbations are conventionally treated with oral, rectal and/or intravenous corticosteroids often in combination with sulphasalazine or 5-ASA. Treatment fails in severe relapses of UC affect between 20 and 40% [42–44]. Some of these none responders will be considered for colectomy although more recently cyclosporin A has been advocated for these corticosteroid-refractory patients [45–48].

    View all citing articles on Scopus
    View full text